about 2 months ago Feasibility of Tumor-Informed Circulating Tumor DNA (ctDNA) for Molecular Residual Disease (MRD) Assessment in Pediatric Patients with Solid Read More
about 2 months ago Personalized circulating tumor (ct)DNA for monitoring disease status in head and neck squamous cell carcinoma Read More
about 2 months ago Longitudinal Analysis of Circulating Tumor DNA in Localized and Metastatic Urothelial Cancer Read More
about 2 months ago Association Between Circulating Tumor DNA and Recurrence-Free Survival in Patients with Resected Stage III Melanoma Read More
about 2 months ago A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic vari Read More
about 2 months ago Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca Read More
about 2 months ago Trial in Progress: Randomized phase III study comparing suspension or continuation of PD-1 Pathway Blockade for patients with advanced non-s Read More
about 2 months ago Abstract # 518: ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1 Read More
about 2 months ago Abstract 3598: Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosi Read More
about 2 months ago Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t Read More
about 2 months ago Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal j Read More
about 2 months ago Genomic alterations in early-onset versus average-onset stage IV colorectal cancer Read More
about 2 months ago Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-ins Read More
about 1 year ago ASCO 2023 - Circulating Tumor DNA and Association with CAR-T Cell Therapy Response in Gastric and Pancreatic Cancer Patients Read More
about 1 year ago ASCO 2023 - Utilization of Circulating Tumor DNA Analysis to Detect Minimal Residual Disease Post-surgery and Disease Progression in Metasta Read More
about 1 year ago ASCO 2023 - Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcin Read More
about 1 year ago ASCO 2023 - Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updat Read More
about 1 year ago ASCO 2023 - Circulating Tumor Dna As A Marker Of Recurrence Risk In Locoregional Esophagogastric Cancers With Pathologic Complete Response Read More
about 1 year ago ASCO 2023 - Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected Read More
about 1 year ago ASCO 2023 - Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma Read More